[go: up one dir, main page]

AU2003290363A8 - Therapeutic use of selective noradrenaline reuptake inhibitors - Google Patents

Therapeutic use of selective noradrenaline reuptake inhibitors

Info

Publication number
AU2003290363A8
AU2003290363A8 AU2003290363A AU2003290363A AU2003290363A8 AU 2003290363 A8 AU2003290363 A8 AU 2003290363A8 AU 2003290363 A AU2003290363 A AU 2003290363A AU 2003290363 A AU2003290363 A AU 2003290363A AU 2003290363 A8 AU2003290363 A8 AU 2003290363A8
Authority
AU
Australia
Prior art keywords
therapeutic use
reuptake inhibitors
noradrenaline reuptake
selective noradrenaline
selective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003290363A
Other versions
AU2003290363A1 (en
Inventor
John Gary Montana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paradigm Therapeutics Ltd
Original Assignee
Amedis Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0230135A external-priority patent/GB0230135D0/en
Priority claimed from GB0316203A external-priority patent/GB0316203D0/en
Application filed by Amedis Pharmaceuticals Ltd filed Critical Amedis Pharmaceuticals Ltd
Publication of AU2003290363A1 publication Critical patent/AU2003290363A1/en
Publication of AU2003290363A8 publication Critical patent/AU2003290363A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003290363A 2002-12-24 2003-12-23 Therapeutic use of selective noradrenaline reuptake inhibitors Abandoned AU2003290363A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0230135.6 2002-12-24
GB0230135A GB0230135D0 (en) 2002-12-24 2002-12-24 Compounds and their uses
GB0316203A GB0316203D0 (en) 2003-07-10 2003-07-10 Compounds and their use
GB0316203.9 2003-07-10
PCT/GB2003/005693 WO2004058353A2 (en) 2002-12-24 2003-12-23 Therapeutic use of selective noradrenaline reuptake inhibitors

Publications (2)

Publication Number Publication Date
AU2003290363A1 AU2003290363A1 (en) 2004-07-22
AU2003290363A8 true AU2003290363A8 (en) 2004-07-22

Family

ID=32683993

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003290363A Abandoned AU2003290363A1 (en) 2002-12-24 2003-12-23 Therapeutic use of selective noradrenaline reuptake inhibitors

Country Status (2)

Country Link
AU (1) AU2003290363A1 (en)
WO (1) WO2004058353A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0216027D0 (en) 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
CA2512022A1 (en) 2003-01-13 2004-07-29 Dynogen Pharmaceuticals, Inc. Method of treating nausea, vomiting, retching or any combination thereof
AP2006003771A0 (en) 2004-04-30 2006-10-31 Warner Lambert Co Substituted morpholine compounds for the treatmentof central nervous system disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH385851A (en) * 1961-03-03 1964-12-31 Geigy Ag J R Process for the preparation of N-heterocyclic compounds
EP0319061A1 (en) * 1987-11-28 1989-06-07 Akzo N.V. Medicament with antiemetic action
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
WO1998050044A1 (en) * 1997-05-07 1998-11-12 Algos Pharmaceutical Corporation Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain
EP1017695A4 (en) * 1997-09-26 2002-01-16 Univ Monash SEPARATION OF OPTICALLY ACTIVE CONNECTIONS
PT1257277E (en) * 2000-02-24 2005-09-30 Pharmacia & Upjohn Co Llc NEW DRUG COMBINATIONS
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
NZ526801A (en) * 2001-01-02 2005-07-29 Upjohn Co Norepinephrine reuptake inhibitor i.e. reboxetine and neuroleptic to treat disorders of the central nervous system
WO2002076461A1 (en) * 2001-03-26 2002-10-03 Serdar Murat Dursun Combination of reboxetine and citalopram

Also Published As

Publication number Publication date
WO2004058353A2 (en) 2004-07-15
AU2003290363A1 (en) 2004-07-22
WO2004058353A3 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
IL164778A0 (en) Therapeutic use of selective pde10 inhibitors
GB0325192D0 (en) Method of use
EP1549316A4 (en) INHIBITORS OF TFGbeta
IL173174A0 (en) Inhibitors of akt activity
IL164703A0 (en) ImidazoÄ1,2-AÜpyrazin-8-ylamines method of making and method of use thereof
EP1511488A4 (en) Human adam-10 inhibitors
IL172063A0 (en) N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors
IL165475A0 (en) Nitrooxyderivatives of eyclooxygenase-2 inhibitors
EP1494678A4 (en) Method of hormonal therapy
GB0211396D0 (en) New use of ramatroban
GB0219660D0 (en) Therapeutic use
PL373523A1 (en) Indol-2-ones as selective inhibitors of cyclooxygenase-2
GB0210741D0 (en) Methods of therapy
GB0206415D0 (en) Deracemisation of amines
AU2003290363A8 (en) Therapeutic use of selective noradrenaline reuptake inhibitors
GB0208897D0 (en) New method of treatment
GB0217493D0 (en) Novel methods of treatment
GB0221712D0 (en) Methods of treatment
TW559073U (en) Improved massage stem of massage bar
GB0214407D0 (en) Enabling use of encrypted data
AU2003231937A8 (en) Therapeutic methods
HUP0203929D0 (en) New use of substituted alkyl-piridazinone derivatives
AU2003293581A8 (en) Method of identifying therapeutic agents
GB0210210D0 (en) Treatment of hydrocarbons
PL356853A1 (en) Application of bacteriphages

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase